Xellia ApS is a Danish multinational pharmaceutical and life sciences company headquartered in Copenhagen specialized in the production of anti-biotics, including Vancomycin and Bacitracin.
The company's US base of operations is in Buffalo Grove, Illinois, with additional facilities in Ohio, and North Carolina. In 2018, Xellia's sales in the United States accounted for 60% of its total revenue.
Products The company's main output is bulk drug chemicals which are wholesaled to other companies for packaging and distribution. Recently some prepackaged goods have been produced.
Active drug substances manufactured are:produktet listen er hentet fra Api på xellia.com 15. august 2014 og supplert med informasjon fra Vår arv hentes samme dag ATC Substance Structural formula Formulation for sale Production started D06AX05 (WHO) (FK)J01XX10 (WHO) (FK)R02AB04 (WHO) (FK)QA07AA93 (WHO) (FK) Bacitracin (MT) Bacitracin 1952 D06AX05 (WHO) (FK)J01XX10 (WHO) (FK)R02AB04 (WHO) (FK)QA07AA93 (WHO) (FK) Bacitracin (MT) Bacitracin zinc 1958 Colistimethate natrium (CMS) A07AA10 (WHO) (FK)J01XB01 (WHO) (FK)QJ51XB01 (WHO) (FK) Colistin Colistin sulfate 1969 J01X X09 Daptomycin (MT) Daptomycin R02AB30 (WHO) (FK) Gramicidin A07AA05 (WHO) (FK)J01XB02 (WHO) (FK)S01AA18 (WHO) (FK)S02AA11 (WHO) (FK)S03AA03 (WHO) (FK)QJ51XB02 (WHO) (FK) Polymyxin B (MT) Polymyxin B-sulfate 1968 J01GB01 (WHO) (FK)S01AA12 (WHO) (FK) Tobramycin (MT) Tobramycin sulfate 2005 D06AX08 (WHO) (FK)R02AB02 (WHO) (FK)S01AA05 (WHO) (FK) Tyrothricin Tyrothricin A07AA09 (WHO) (FK)J01XA01 (WHO) (FK) Vancomycin (MT) Vancomycin hydrochloride 2003 A01AB04 (WHO) (FK)A07AA07 (WHO) (FK)G01AA03 (WHO) (FK)J02AA01 (WHO) (FK) Amfotericin B (MT) Amfotericin B 1985 J02AX04 (WHO) (FK) Caspofungin (MT) Caspofungin acetate D07AC17 (WHO) (FK)R01AD08 (WHO) (FK)R01AD58 (WHO) (FK)R03BA05 (WHO) (FK) Fluticasone (MT) Fluticasone propionate D07AC13 (WHO) (FK)R01AD09 (WHO) (FK)R03BA07 (WHO) (FK) Mometasone (MT) Mometasone furoate
Discontinued products Previously the company also produced: Ingredient Produced Neomycin 1952-? Tetracycline 1961-?
Partnerships
In 2019, Xellia partnered with Civica Rx to produce generic Vancomycin and Daptomycin. The partnership's stated aim is to remedy chronic drug shortages that have affected the American pharmaceutical market.
China-US Trade War
Xellia has been discussed as a potential alternative to Chinese companies for anti-biotic primary ingredients in the context of the China-United States trade war.
See also List of Danish companies List of pharmaceutical companies
References